YOLFTbeta
Keros Therapeutics Inc

Keros Therapeutics Inc

KROS · NASDAQ · Healthcare / Biotechnology

10.30USD+0.22 (+2.18%)

Price History

Full chart

Market Stats

Previous Close10.08
Open10.06
Day Range9.55 – 10.55
52-Week Range9.69 – 22.55
Volume167.04K
Market Cap223.65M
P/E (TTM)0.00
Forward P/E48.78
EPS-3.22
Dividend Yield0.00%
Beta1.02
50-Day Avg10.86
200-Day Avg13.13

About

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jasbir S. Seehra Ph.D.
  • Employees92
  • Headquarters1050 Waltham Street, Lexington, MA, United States, 02421, USA
  • Websitehttps://www.kerostx.com

Leadership

  • Dr. Jasbir S. Seehra Ph.D.President, CEO & Director · b. 1956
  • Ms. Esther Cho J.D.Chief Legal Officer & Secretary · b. 1989
  • Justin FrantzHead of Investor Relations
  • Dr. Lorena Lerner Ph.D.Chief Scientific Officer · b. 1972

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue10.00M10.00M2.50M20.10M20.00M151.00K3.55M244.06M
Growth (%)-0.00%-75.00%+704.00%-0.50%-99.25%+2250.99%+6774.96%
Cost of Revenue10.11M17.35M605.00K898.00K1.61M815.00K1.23M1.51M
Gross Profit-111.00K-7.35M-605.00K20.10M-1.61M151.00K3.55M242.55M
Gross Margin-1.11%-73.48%-24.20%100.00%-8.08%100.00%100.00%99.38%
Operating Expense1.58M3.21M46.05M76.47M113.17M170.09M214.38M171.93M
Operating Income-1.69M-10.56M-46.66M-56.37M-114.79M-169.94M-210.83M70.62M
Operating Margin-16.91%-105.63%-1866.28%-280.46%-573.95%-112543.71%-5938.96%28.94%
EBITDA-774.00K-11.89M-44.92M-56.35M-104.00M-152.18M-185.82M93.41M
EBITDA Margin-7.74%-118.90%-1796.88%-280.35%-520.02%-100779.47%-5234.48%38.27%
Net Income-1.33M-12.34M-45.36M-58.74M-104.68M-152.99M-187.35M87.01M
Net Income Margin-13.35%-123.44%-1814.44%-292.26%-523.39%-101319.21%-5277.55%35.65%
R&D10.11M17.38M33.86M55.14M87.27M135.26M173.63M129.64M
R&D as % of Total Revenue101.11%173.79%1354.40%274.34%436.32%89574.83%4890.96%53.12%
Interest Expense6.00K8.00K6.00K4.00K1.00K00-
Interest Expense % of Total Revenue0.06%0.08%0.24%0.02%0.01%0.00%0.00%-

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets27.41M10.96M269.44M255.25M306.78M370.02M615.89M338.02M
Total Liabilities14.65M5.50M7.72M12.08M29.36M37.81M44.33M34.89M
Total Equity12.76M5.45M261.72M243.17M277.42M332.21M571.55M303.13M
Cash23.26M7.02M265.88M230.04M279.05M331.15M559.93M287.42M
Total Debt2.56M5.33M899.00K1.09M13.27M14.44M18.86M16.88M
Net Debt-22.47M-5.75M-264.98M-228.95M-265.78M-316.70M-541.07M-270.53M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow7.04M-16.00M-36.89M-62.15M-70.06M-124.51M-160.87M107.50M
Investing Cash Flow-217.00K-271.00K-294.00K-1.02M-1.24M-2.46M-1.93M-1.55M
Financing Cash Flow11.46M14.00K296.04M28.55M120.31M178.96M391.82M-378.47M
Capital Expenditure217.00K271.00K294.00K1.02M1.24M2.46M1.93M1.55M
Free Cash Flow6.83M-16.27M-37.19M-63.17M-71.30M-126.97M-162.80M105.95M
FCF to OCF96.92%101.69%100.80%101.65%101.77%101.98%101.20%98.56%

Earnings

Report DateMay 22, 2020Aug 13, 2020Nov 10, 2020Mar 25, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Mar 9, 2022May 5, 2022Aug 4, 2022Nov 3, 2022Mar 3, 2023May 4, 2023Aug 7, 2023Nov 6, 2023Feb 28, 2024May 8, 2024Aug 7, 2024Nov 6, 2024Feb 26, 2025May 6, 2025Aug 6, 2025Nov 5, 2025Mar 4, 2026Apr 30, 2026Aug 3, 2026Nov 4, 2026
EPS Estimate-0.80-0.67-0.59-0.57-0.58-0.65-0.72-0.92-0.86-1.07-1.26-1.10-1.14-1.35-1.35-1.37-1.33-1.25-1.28-0.430.01-1.13-1.11-0.45-0.73-1.25-0.96
EPS Actual-5.11-0.62-0.60-0.49-0.68-0.67-0.87-0.30-1.01-1.13-0.92-1.09-1.26-1.27-1.33-1.34-1.21-1.25-1.41-1.143.62-0.76-0.18-0.86-1.21-1.45-
Surprise-538.75%7.46%-1.69%14.04%-17.24%-3.08%-20.83%67.39%-17.44%-5.61%26.98%0.91%-10.53%5.93%1.48%2.19%9.02%0.00%-10.16%-166.98%36100.00%32.74%83.78%-91.11%-66.23%-16.00%-
TimingPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap223.65M
Enterprise Value-11.29M
Trailing P/E0.00
Forward P/E48.78
Price / Sales14.90
Price / Book0.88
EPS-3.22
Book Value13.23
Revenue (TTM)15.01M
Gross Profit (TTM)-58.34M
EBITDA-96.87M
Profit Margin0.00%
Operating Margin-655.84%
Return on Equity-17.16%
Return on Assets-11.78%
Shares Outstanding19.83M
Shares Float17.76M
Beta1.02
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 13 analystsTarget 19.83
  • Strong Buy
    5
  • Buy
    2
  • Hold
    6

Ownership Breakdown

Institutions
95.19%
Insiders
3.96%
Retail / Other
0.85%

Top Institutional Holders

  • BlackRock Inc
    2.41M12.16%
  • Nantahala Capital Management, LLC
    1.36M6.86%
  • Vanguard Capital Management, LLC
    831.42K4.19%
  • Orbimed Advisors LLC
    759.15K3.83%
  • Qube Research & Technologies
    724.93K3.66%
  • Jacobs Levy Equity Management, Inc.
    706.07K3.56%
  • Federated Hermes Inc
    700.43K3.53%
  • Vanguard Portfolio Management, LLC
    682.04K3.44%
  • Geode Capital Management, LLC
    681.46K3.44%
  • Madison Avenue Partners, LP
    626.58K3.16%
  • Arrowstreet Capital Limited Partnership
    590.25K2.98%
  • State Street Corp
    561.73K2.83%
  • Dimensional Fund Advisors, Inc.
    460.54K2.32%
  • Renaissance Technologies Corp
    453.48K2.29%
  • AQR Capital Management LLC
    406.56K2.05%
  • Citadel Advisors Llc
    396.10K2.00%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    595.32K3.00%
  • iShares Russell 2000 ETF
    467.75K2.36%
  • BlackRock Advantage Small Cap Core Instl
    458.76K2.31%
  • Federated Hermes MDT Small Cap Core IS
    382.34K1.93%